Amgen Inc. (AMGN) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Amgen's CFO, Peter Griffith, highlighted the company's strong first-quarter 2025 performance at the Goldman Sachs Global Healthcare Conference, noting a 9% increase in revenue and a 24% rise in non-GAAP EPS year-over-year, driven by double-digit growth from 14 products. Key growth drivers include Repatha, which saw a 27% increase in Q1 revenue to $656 million, reflecting continued robust growth in the cardiovascular market.

Analysis

Amgen Inc. (AMGN) showcased significant business momentum during the Goldman Sachs 46th Annual Global Healthcare Conference, as articulated by CFO Peter H. Griffith. The company reported robust first-quarter 2025 financial results, with revenues increasing 9% year-over-year and non-GAAP EPS surging 24% year-over-year. This performance was broad-based, supported by 14 individual products delivering double-digit growth in the first quarter. A key contributor to this growth is Repatha, a cardiovascular treatment, which achieved Q1 2025 revenue of $656 million, marking a 27% increase from the prior year and establishing it as a multi-billion dollar run-rate product. Management highlighted the persistent global impact of cardiovascular disease, underpinning their expectation for continued robust growth for Repatha, reflecting optimism about the company's core general medicine franchise and advancing pipeline.

Key Decisions for Investors

• Investors should note Amgen's strong Q1 2025 financial performance, particularly the 9% revenue and 24% non-GAAP EPS growth, as indicative of current operational strength.
• The diversified growth across 14 products suggests a resilient portfolio, reducing reliance on a single asset; continued monitoring of these individual product trajectories is advisable.
• Repatha's 27% Q1 revenue growth to $656 million positions it as a critical value driver; its sustained performance in the large cardiovascular market warrants close attention for future growth assessments.
• Consider management's positive commentary and the 'strongly positive' sentiment (0.8 for AMGN) as a reflection of confidence in ongoing business momentum and pipeline development.